Connect Biopharma (CNTB) news
Recent news
Connect Biopharma Holdings Ltd: Oppenheimer initiates coverage with outperform rating; target price $8
On July 9, 2026, Oppenheimer initiated coverage of Connect Biopharma Holdings Ltd (Nasdaq: CNTB) with an "Outperform" rating and a target price of $8 per share. This move follows a series of recent analyst actions and reflects growing investor interest in the clinical-stage biopharmaceutical…
AInvest Wire · Jul 9, 2026Connect Biopharma - to report topline data from Seabreeze Stat asthma study in early September 2026
AInvest Wire · Jun 17, 2026Simcere Pharmaceutical - obtains exclusive promotion rights for Pumecitinib gel in China, Hong Kong, Macau
Simcere Pharmaceutical Group Limited has recently expanded its portfolio in the autoimmune and inflammatory disease space through a strategic collaboration with Connect Biopharma. In 2023, the company entered into an exclusive license and collaboration agreement for Rademikibart, an IL-4Rα…
AInvest Wire · Jun 1, 2026Connect Biopharma Announces New Leadership and Chair of the Board of Directors
Connect Biopharma Announces New Leadership and Chair of the Board of Directors The biopharmaceutical industry continues to evolve as companies adapt to the changing landscape of healthcare and research. One such company, Connect Biopharma, recently announced new leadership and the appointment of a…
AInvest Wire · Jun 12, 2024ImportantConnect Biopharma surges 33% premarket as its study met primary endpoint
AInvest Wire · Dec 12, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.